Combined chemotherapy radiotherapy management of stage 3 Hodgkin's disease.
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D001772:Blood Cell Count; D001792:Blood Platelets / Q000187:drug effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*; D011344:Procarbazine / Q000008:administration & dosage / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D012075:Remission, Spontaneous; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001565:Benzoates; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone